Isotretinoin remains the most effective treatment available for moderate-to-severe acne vulgaris, yet a substantial share of the patients who need it most are reluctant to take it. A new cross-sectional study from Uşak University in Turkey has now quantified just how widespread this reluctance is, introducing a validated questionnaire designed to measure what the researchers call isotretinoin phobia. The work, published in the Archives of Dermatological Research, offers clinicians a practical instrument for identifying patients whose fears may derail treatment before a single capsule is swallowed.
The research team, led by Simge Ünal Işık of the Department of Dermatology and Venereology at Uşak University Faculty of Medicine, together with colleagues from Kyrenia Dr. Akçiçek State Hospital and Uşak Training and Research Hospital, recruited 312 patients diagnosed with moderate-to-severe acne vulgaris between June and December 2025. Participants completed a five-part questionnaire that included the newly developed 11-item Isotretinoin Phobia Scale. The scale demonstrated strong internal consistency, with a Cronbach’s alpha of 0.86, a statistical measure indicating that the items reliably capture the same underlying construct of fear and avoidance related to the drug.
The findings reveal that apprehension about isotretinoin is nearly universal among this patient population, even if it reaches clinically significant intensity in a smaller subgroup. Of the 312 participants, who had a mean age of 20.16 years with a standard deviation of 3.96, 45.2 percent recorded low phobia scores, 50.3 percent showed moderate levels, and 4.5 percent exhibited high phobia. Using receiver operating characteristic analysis, the researchers established a cut-off score of 21.5 for clinically significant phobia, an approach that yielded an area under the curve of 0.806, indicating good discriminatory ability in distinguishing patients whose fears are severe enough to influence clinical decisions.
One of the more counterintuitive results concerns education. Higher educational attainment correlated positively with phobia scores, with a Spearman correlation coefficient of 0.191 and a p-value below 0.001. Rather than reassuring patients, greater formal knowledge appears to be associated with heightened concern, a pattern the authors’ data suggest may reflect exposure to alarming information about the drug’s side-effect profile rather than a balanced appraisal of risk. This finding echoes earlier research on medication phobias, including studies of corticosteroid phobia in atopic dermatitis, where fear frequently outpaces documented danger.
Experience, by contrast, seems to be an antidote. Patients who had previously used isotretinoin showed significantly lower phobia scores than those who had never taken the drug, with the difference reaching statistical significance at p = 0.003. This inverse relationship between direct exposure and fear suggests that much of the anxiety surrounding isotretinoin is anticipatory, built on secondhand accounts and online narratives rather than lived experience. It also implies that first-time patients represent the group most in need of structured counseling, since their fears have not yet been tested against reality.
The clinical consequences of significant phobia were substantial. Patients scoring above the 21.5 cut-off were more likely to refuse treatment altogether, reported impaired quality of life, and displayed increased healthcare-seeking behavior. Notably, however, phobia was not associated with treatment discontinuation among those who did start therapy. In other words, fear acts primarily as a gatekeeping barrier: it prevents patients from beginning isotretinoin, but once treatment is underway, the same fears rarely cause them to stop. This distinction matters for clinicians, because the window of opportunity for intervention lies before the prescription is written.
The study also identified which specific concerns dominate the phobic response. Behavioral hesitation, social influence, and fear of side effects emerged as the most common drivers of anxiety. Social influence is particularly noteworthy in the era of social media, where anecdotal reports of adverse effects can spread rapidly and shape patient perceptions before any medical consultation takes place. Prior work has even explored social media platforms as surveillance tools for monitoring isotretinoin side effects, underscoring how deeply online discourse has penetrated the therapeutic relationship. Related studies have documented similar concerns among parents of adolescents and among university students in Switzerland, indicating that isotretinoin hesitancy is a cross-cultural phenomenon.
To identify the factors predicting clinically significant phobia, the researchers employed logistic regression alongside chi-square tests and correlation analyses. The statistical framework allowed them to separate demographic and experiential variables that independently predict high fear from those that do not. The resulting model, anchored by the validated cut-off score, gives dermatologists a straightforward triage tool: a patient scoring above 21.5 on the 11-item scale can be flagged for intensified counseling, while those below the threshold may proceed with standard education about the drug’s risk profile.
The broader significance of the study lies in reframing treatment refusal not as irrational stubbornness but as a measurable, predictable, and modifiable psychological barrier. Isotretinoin’s adverse-effect profile, which includes mucocutaneous dryness, lipid changes, and stringent teratogenicity precautions, is well documented, and legitimate monitoring requirements exist. Yet the gap between perceived and actual risk has long frustrated dermatologists, particularly because untreated moderate-to-severe acne can leave permanent scarring and lasting psychological damage. Earlier research has shown that acne relapse and the need for retrial with isotretinoin remain common clinical challenges, making first-line adherence all the more valuable.
The authors conclude that isotretinoin phobia represents a significant barrier to effective acne management and that early recognition is crucial. By deploying the Isotretinoin Phobia Scale at the point of care, clinicians could detect at-risk patients before refusal hardens into a decision, then direct targeted counseling toward the specific concerns, whether behavioral hesitation, social pressure, or fear of side effects, that drive each patient’s anxiety. Given that previous users report markedly less fear, structured education that sets accurate expectations may convert the most anxious first-time patients into confident ones, improving adherence, protecting quality of life, and ultimately preventing the long-term complications of untreated severe acne.
Subject of Research: Isotretinoin phobia and its clinical impact in moderate-to-severe acne vulgaris
Article Title: Fear of isotretinoin in moderate-to-severe acne: clinical impact and a new assessment approach
Article References: Ünal Işık, S., Yüksek, T., Koç Yıldırım, S., & Işık, L. (2026). Fear of isotretinoin in moderate-to-severe acne: clinical impact and a new assessment approach. Archives of Dermatological Research, 318(1), Article 441. https://doi.org/10.1007/s00403-026-04905-z
Image Credits: AI Generated
DOI: 10.1007/s00403-026-04905-z
Keywords: isotretinoin, acne vulgaris, phobia, dermatology, treatment adherence, quality of life, patient counseling, Isotretinoin Phobia Scale, side effects, medication hesitancy, cross-sectional study, skin health
News Source: Ophelia Keating. (October 7, 2026). Acne Patients’ Fear of Isotretinoin Measured by New Phobia Scale. Scienmag.
